| Literature DB >> 28212621 |
Alvaro Sanchez1, Gonzalo Grandes2, Josep M Cortada3, Haizea Pombo1, Catalina Martinez1, Mary Helen Corrales4, Enrique de la Peña5, Justo Mugica6, Esther Gorostiza7.
Abstract
BACKGROUND: Process evaluation is recommended to improve the understanding of underlying mechanisms related to clinicians, patients, context and intervention delivery that may impact on trial or program results, feasibility and transferability to practice. The aim of this study was to assess the feasibility of the Prescribe Healthy Life (PVS from the Spanish "Prescribe Vida Saludable") implementation strategy for enhancing the adoption and implementation of an evidence-based health promotion intervention in primary health care.Entities:
Keywords: Health promotion; Implementation; Primary Health Care; Process evaluation
Mesh:
Year: 2017 PMID: 28212621 PMCID: PMC5316192 DOI: 10.1186/s12875-017-0585-5
Source DB: PubMed Journal: BMC Fam Pract ISSN: 1471-2296 Impact factor: 2.497
Professional and practice level participation, and patient demographic and clinical characteristics, by center
| Center 1 | Center 2 | Center 3 | Center 4 | Total | |
|---|---|---|---|---|---|
| Professional level | |||||
| Family physicians | 11/13 | 5/6 | 3/4 | 4/4 | 23/27 (85%) |
| Nurses | 9/13 | 6/8 | 4/5 | 6/6 | 25/32 (78%) |
| Administrative personnel | 5/6 | 2/5 | 3/4 | 4/4 | 14/19 (74%) |
| Pediatricians | 0/2 | 2/2 | 0/1 | 1/1 | 3/6 (50%) |
| Midwifes | 0/2 | 0/1 | − | 1/1 | 1/4 (25%) |
| Othersa | − | − | − | 2/2 | |
| Total | 25/36 (69%) | 15/22 (68%) | 10/14 (71%) | 18/18 (100%) | 68/90 (75%) |
| Practice level | |||||
| Initial commitment | 11/14 | 7/8 | 4/4 | 5/5 | 27/32 (84%) |
| Assessed (A1) 50% of target patients | 2/11 | 4/7 | 2/4 | 5/5 | 13/27 (48%) |
| Advised (A2) 25% of target patients | 4/11 | 5/7 | 1/4 | 5/5 | 15/27 (55%) |
| Assisted (A4) 10% of target patients | 3/11 | 3/7 | 2/4 | 5/5 | 13/27 (48%) |
| Patient level | |||||
| Male sex | 5126 (49.4%) | 3215 (54.6%) | 1266 (49.3%) | 1760 (48.4%) | 11367 (50.6%) |
| (48.4%–50.4%) | (53.4%–55.9) | (47.4%–1.2%) | (46.8%–50.0%) | (49.9%–51.3%) | |
| Age, years | |||||
| 10–19 | 273 (2.6%) | 551 (9.4%) | 373 (14.5%) | 367 (10.1%) | 1564 (7%) |
| (2.3%–2.9%) | (8.6%–10.1%) | (13.2%–5.9%) | (9.1%–11.15) | (6.6%–7.3%) | |
| 20–45 | 5713 (55.1%) | 3585 (60.9%) | 1214 (47.3%) | 1881 (51.7%) | 12393 (55.2%) |
| (54.1%–56.0%) | (59.7%–62.2%) | (45.3%–9.2%) | (50.1%–3.4%) | (54.5%–55.8%) | |
| 46–65 | 4387 (42.3%) | 1747 (29.7%) | 981 (38.2%) | 1387 (38.2%) | 8502 (37.9%) |
| (41.3%–43.2%) | (28.5%–30.8%) | (36.3%–40.1%) | (36.6%–9.7%) | (37.2%–38.5%) | |
| Health problems | |||||
| Cancerb | 215 (2.2%) | 88 (1.6%) | 41 (1.6%) | 65 (1.8%) | 409 (1.9%) |
| (1.9%–2.4%) | (1.3%–2.0%) | (1.4%–2.3%) | (1.1%–2.2%) | (1.7%–2.1%) | |
| Neurological disordera | 377 (3.8%) | 206 (3.8%) | 80 (3.2%) | 165 (4.6%) | 828 (3.9%) |
| (3.4%–4.2%) | (3.4%/4.4%( | (2.5%–3.9%) | (3.9%–5.3%) | (3.6%–4.1%) | |
| Cardiovascular diseasea | 1371 (13.8%) | 610 (11.4%) | 268 (10.8%) | 481 (13.5%) | 2730 (12.8%) |
| (13.1%–14.5%) | (10.6%–12.3%) | (9.6%–12.1%) | (12.4%–14.6%) | (12.3%–13.2%) | |
| Musculoskeletal disordera | 637 (6.4%) | 311 (5.8%) | 121 (4.9%) | 268 (7.5%) | 1337 (6.3%) |
| (5.9%–6.9%) | (5.2%–6.4%) | (4.0%–5.7%) | (6.7%–8.4%) | (5.9%–6.6%) | |
| Mental health problema | 1415 (14.2%) | 1032 (19.3%) | 357 (14.4%) | 647 (18.2%) | 3451 (16.2%) |
| (13.5%–14.9%) | (18.2–20.4%) | (13.0%–15.8%) | (16.9%–19.5%) | (15.7%–16.7%) | |
| Respiratory diseasea | 398 (4.0%) | 342 (6.4%) | 116 (4.7%) | 211 (5.9%) | 1067 (5.0%) |
| (3.6%–4.4%) | (5.7%–7.0%) | (3.8%–5.5%) | (5.2%–6.7%) | (4.7%–5.3%) | |
| Digestive diseasea | 415 (4.2%) | 259 (4.8%) | 84 (3.4%) | 153 (4.3%) | 911 (4.3%) |
| (3.8%–4.6%) | (4.3%–5.4%) | (2.7%–4.1%) | (3.6%–5.0%) | (4.0%–4.5%) | |
| Metabolism-related diseasea | 873 (8.7%) | 383 (7.2%) | 143 (5.8%) | 257 (7.2%) | 1656 (7.8%) |
| (8.2%–9.3%) | (6.5%–7.8%) | (4.8%–6.7%) | (6.4%–8.1%) | (7.4%–8.1%) | |
| Othera | 621 (6.2%) | 449 (8.4%) | 157 (6.3%) | 250 (7.0%) | 1477 (6.9%) |
| (5.8%–6.7%) | (7.6%–9.1%) | (5.4%–7.3%) | (6.2%–7.9%) | (6.6%–7.3%) | |
| No chronic health problems | 5885 (59.2%) | 3098 (57.9%) | 1560 (62.9%) | 1954 (54.9%) | 12497 (58.6%) |
| (58.2%–60.2%) | (56.6%–59.3%) | (61.0%–64.8%) | (53.3%–56.6%) | (57.9%–59.3%) | |
| Deprivation Index | |||||
| I | 48 (0.5%) | 230 (4.3%) | 536 (21.4%) | 87 (2.4%) | 901 (4.2%) |
| (0.3%–0.6%) | (3.7%–4.8%) | (19.8%–3.0%) | (1.9%–2.9%) | (3.9%–4.5%) | |
| II | 3456 (34.8%) | 176 (3.3%) | 1848 (73.8%) | 2094 (58.8%) | 7574 (35.4%) |
| (33.8%–35.7%) | (2.8%–3.8%) | (72.1%–5.5%) | (57.2%–60.4%) | (34.8%–36.1%) | |
| III | 4867 (48.9%) | 151 (2.8%) | 43 (1.7%) | 46 (1.3%) | 5107 (23.9%) |
| (48.0%–49.9%) | (2.4%–3.2%) | (1.2%–2.2%) | (0.9%–1.7%) | (23.3%–24.5%) | |
| IV | 907 (9.1%) | 167 (3.1%) | 35 (1.4%) | 289 (8.1%) | 1398 (6.6%) |
| (8.5%–9.7%) | (2.6%–3.6%) | (0.9%–1.8%) | (7.2%–9.0% | (6.2%–6.95) | |
| V | 664 (6.7%) | 4637 (86.5%) | 43 (1.7%) | 1043 (29.3%) | 6387 (29.9%) |
| (6.2%–7.2%) | (85.6%–87.4%) | (1.2%–2.2%) | (27.8%–30.8%) | (29.3%–30.5%) | |
| Failure to adhere to ≥1 lifestyle recommendation | 3206 (84.5%) | 3070 (95.7%) | 1536 (93.7%) | 2693 (89.5%) | 10505 (90.2%) |
| Insufficient physical activity | 1979 (53.1%) | 2250 (70.8%) | 728 (61.9%) | 1570 (58.3%) | 6527 (60.6%) |
| Insufficient fruit and vegetable consumption | 2507 (67.1%) | 2766 (86.9%) | 888 (76.6%) | 1888 (70.1%) | 8049 (74.7%) |
| Smoker | 1009 (27.3%) | 1146 (36.6%) | 541 (33.8%) | 978 (32.6%) | 3674 (32.1%) |
aDentist and family planning physician
b N = 21323
Implementation indicators at target and included patient population levels, by center and lifestyle habit
| Center 1 | Center 2 | Center 3 | Center 4 | Total | |
|---|---|---|---|---|---|
|
| 10373 | 5883 | 2568 | 3635 | 22459 |
| A1 at least on 1 lifestyle | 3792 (36.6%) | 3209 (54.5%) | 1640 (63.7%) | 3009 (82.8%) | 11650 (51.9%) |
| (35.6–37.5%) | (53.3–55.8%) | (62.0–65.7%) | (81.5–84.0%) | (51.2–52.5%) | |
| A2 at least on 1 lifestyle | 2318 (22.3%) | 2170 (36.9%) | 809 (31.5%) | 2136 (58.7%) | 7433 (33.1%) |
| (21.5–23.1%) | (35.6–38.1%) | (29.7–33.3%) | (57.2–60.4%) | (32.5–33.7%) | |
| A4 at least on 1 lifestyle | 840 (8.1%) | 406 (6.9%) | 377 (14.7%) | 552 (15.2%) | 2175 (9.7%) |
| (7.6–8.6%) | (6.2–7.5%) | (13.3–16.1%) | (14.0–16.3%) | (9.3–10.1%) | |
| A5 at least on 1 lifestyle | 231 (2.2%) | 198 (3.4%) | 177 (6.9%) | 218 (6.0%) | 824 (3.7%) |
| (1.9–2.5%) | (2.95–3.8%) | (5.9–7.9%) | (5.2–6.7%) | (3.4–3.9%) | |
| Physical Activity (PA) | |||||
| A1_PA | 3727 (35.9%) | 3176 (54%) | 1176 (45.8%) | 2692 (74.1%) | 10771 (48.0%) |
| (35.0–36.8%) | (52.7–55.3%) | (43.9–47.7%) | (72.6–75.5%) | (47.3–48.6%) | |
| A2_PA | 1097 (10.6%) | 1148 (19.5%) | 386 (15%) | 1071 (29.5%) | 3702 (16.5%) |
| (10.0–11.2%) | (18.5–20.5%) | (13.6–16.4%) | (28.0–30.9%) | (16.0–17.0%) | |
| A4_PA | 315 (3%) | 123 (2.1%) | 161 (6.3%) | 194 (5.3%) | 793 (3.5%) |
| (2.7–3.4%) | (1.7–2.4%) | (5.3–7.2%) | (4.6–6.1%) | (3.3–3.8%) | |
| A5_PA | 50 (0.5%) | 38 (0.6%) | 68 (2.6%) | 43 (1.2%) | 199 (0.9%) |
| (0.3–0.6%) | (0.4–0.8%) | (2.0–3.2%) | (0.8–1.5%) | (0.8–1.0%) | |
| Diet (DT) | |||||
| A1_DT | 3737 (36%) | 3182 (54.1%) | 1159 (45.1%) | 2693 (74.1%) | 10771 (48.0%) |
| (35.1–36.9%) | (52.8–55.4%) | (43.2–47.0%) | (72.7–75.5%) | (47.3–48.6%) | |
| A2_DT | 1688 (16.3%) | 1848 (31.4%) | 486 (18.9%) | 1407 (38.7%) | 5429 (24.2%) |
| (15.6–17.0%) | (30.2–32.6%) | (17.4–20.4%) | (37.1–40.3%) | (23.6–24.7%) | |
| A4_DT | 549 (5.3%) | 319 (5.4%) | 217 (8.5%) | 353 (9.7%) | 1438 (6.4%) |
| (4.9–5.7%) | (4.8–6.0%) | (7.4–9.5%) | (8.7–10.7%) | (6.1–6.7%) | |
| A5_DT | 154 (1.5%) | 176 (3%) | 110 (4.3%) | 144 (3.9%) | 584 (2.6%) |
| (1.2–1.7%) | (2.5–3.4%) | (3.5–5.1%) | (3.3–4.6%) | (2.4–2.8%) | |
| Tobacco (TB) | |||||
| A1_TB | 3698 (35.6%) | 3133 (53.3%) | 1599 (62.3%) | 2997 (82.4%) | 11427 (50.9%) |
| (34.7–36.6%) | (52.0–54.5%) | (60.4–64.1%) | (81.2–83.7%) | (50.2–51.5%) | |
| A2_TB | 652 (6.3%) | 836 (14.2%) | 227 (8.8%) | 676 (18.6%) | 2391 (10.6%) |
| (5.8–6.7%) | (13.3–15.1%) | (7.7–9.9%) | (17.3–19.7%) | (10.2–11.0%) | |
| A4_TB | 99 (1%) | 60 (1%) | 40 (1.6%) | 67 (1.7%) | 266 (1.2%) |
| (0.8–1.1%) | (0.8–1.3%) | (1.1–2.0%) | (1.4–2.3%) | (1.0–1.3%) | |
| A5_TB | 42 (0.4%) | 17 (0.3%) | 4 (0.2%) | 34 (0.9%) | 97 (0.4%) |
| (0.3–0.5%) | (0.1–0.4%) | (0.0–0.3%) | (0.6–1.2%) | (0.3–0.5%) | |
Note: A1 refers to Assess; A2 refers to Advise; A4 refers to Assist with a prescription for change; and A5 refers to arrange follow-up with a repeat prescription
Fig. 1Cumulative exposure of patients to the main intervention components in the four collaborating centers over the 2-year program implementation period
Characteristics of target population associated with exposure to the main intervention components: Assessment of lifestyles (A1), Advice on lifestyle change (A2), and Prescription of lifestyle change (A4)
| Variables | Adjusted Hazard Ratio (95% CI) | ||||
|---|---|---|---|---|---|
| Assessed (A1) | Advised (A2) | Prescribed (A4) | |||
| Age (unit = 5 years) | 1.05 (1.04–1.06) | 1.04 (1.03–1.05) | 1.04 (1.02–1.06) | ||
| Sex | Female | 1.00 | 1.00 | 1.00 | |
| Male | 0.83 (0.80–0.86) | 0.84 (0.80–0.88) | 0.68 (0.63–0.74) | ||
| Cardiovascular disease | No | 1.00 | 1.00 | 1.00 | |
| Yes | 1.41 (1.33–1.49) | 1.51 (1.42–1.62) | 1.87 (1.67–2.09) | ||
| Musculoskeletal disorder | No | 1.00 | 1.00 | 1.00 | |
| Yes | 1.19 (1.11–1.28) | 1.15 (1.05–1.25) | 1.20 (1.04–1.39) | ||
| Mental health problem | No | 1.00 | 1.00 | 1.00 | |
| Yes | 1.09 (1.04–1.14) | 1.18 (1.11–1.25) | 1.15 (1.03–1.28) | ||
| Respiratory disease | No | 1.00 | 1.00 | 1.00 | |
| Yes | 1.25 (1.15–1.35) | 1.36 (1.24–1.49) | 1.51 (1.29–1.77) | ||
| Digestive disease | No | 1.00 | 1.00 | 1.00 | |
| Yes | 1.12 (1.03–1.23) | 1.12 (1.01–1.24) | 1.25 (1.06–1.49) | ||
| Metabolism-related disease | No | 1.00 | 1.00 | 1.00 | |
| Yes | 1.25 (1.17–1.34) | 1.26 (1.16–1.36) | 1.32 (1.16–1.51) | ||
| Other chronic health problem | No | 1.00 | 1.00 | -- | |
| Yes | 1.13 (1.05–1.21) | 1.14 (1.05–1.24) | -- | ||
| Deprivation Index | High | 1.00 | 1.00 | 1.00 | |
| Medium | 1.18 (1.10–1.27) | 1.17 (1.10–1.25) | 1.14 (0.98–1.33) | ||
| Low | 1.16 (1.10–1.22) | 1.19 (1.11–1.27) | 1.25 (1.11–1.42) | ||
| Center | Center 1 | 1.00 | 1.00 | 1.00 | |
| 0–3 months | Center 2 | 3.42 (3.00–3.90) | 4.23 (3.47–5.16) | 3.24 (2.47–4.25) | |
| Center 3 | 8.54 (7.54–9.66) | 5.04 (4.07–6.25) | 2.06 (1.46–2.89) | ||
| Center 4 | 6.19 (5.48–7.00) | 4.54 (3.70–5.56) | 4.22 (3.25–5.47) | ||
| 3–6 months | Center 2 | 2.97 (2.52–3.48) | 7.43 (5.77–9.56) | 2.62 (1.78–3.88) | |
| Center 3 | 3.55 (2.93–4.30) | 6.91 (5.22–9.15) | 6.55 (4.57–9.38) | ||
| Center 4 | 8.96 (7.78–10.32) | 10.59 (8.27–13.57) | 6.38 (4.54–8.97) | ||
| 6–12 months | Center 2 | 4.42 (4.02–4.85) | 2.81 (2.49–3.18) | 0.95 (0.73–1.23) | |
| Center 3 | 2.37 (2.08–2.70) | 1.43 (1.20–1.69) | 2.16 (1.71–2.73) | ||
| Center 4 | 5.69 (5.17–6.27) | 4.45 (3.97–4.99) | 2.03 (1.64–2.52) | ||
| 12–24 months | Center 2 | 1.01 (0.92–1.12) | 1.52 (1.37–1.68) | 0.41 (0.32–0.53) | |
| Center 3 | 1.26 (1.12–1.42) | 1.01 (0.89–1.15) | 1.24 (1.01–1.52) | ||
| Center 4 | 2.50 (2.27–2.75) | 2.91 (2.65–3.19) | 0.91 (0.75–1.11) | ||